All Phase II articles
-
NewsAbCellera’s ABCL635 delivers positive Phase II data for vasomotor symptoms
In early Phase II data, investigational antibody ABCL635 achieved all primary efficacy endpoints in postmenopausal women experiencing vasomotor symptoms.